TL;DR
A VA study of 600,000 veterans found GLP-1 users were 15 to 20 percent less likely to be diagnosed with substance use disorders.
MSM Perspective
NPR reported the study as a promising but preliminary finding, emphasizing that clinical trials for addiction treatment have not yet been conducted.
X Perspective
X is treating the addiction findings as evidence that GLP-1 drugs operate on the brain's reward system in ways researchers are only beginning to understand.
People taking GLP-1 drugs for type 2 diabetes were 15 to 20 percent less likely to be diagnosed with substance use disorders, according to a study of more than 600,000 veterans published in the BMJ this month. The study, led by Dr. Ziyad Al-Aly at Washington University in St. Louis, tracked patients for up to three years and found reduced diagnoses across alcohol, opioid, cannabis, and stimulant use disorders. [1] [2]
The finding is not entirely surprising. GLP-1 receptors are present in the brain's reward circuitry, and animal studies have shown that the drugs reduce alcohol and cocaine consumption in rodents. What the VA study adds is scale and specificity. Six hundred thousand patients. Three years of follow-up. A consistent signal across multiple substance categories. The researchers also found that GLP-1 users had 50 percent fewer substance-related emergency department visits and lower rates of overdose. [2] [3]
NPR reported the findings on March 10, noting that no clinical trial has yet tested GLP-1 drugs as a treatment for addiction. The VA data is observational, meaning it can show correlation but not prove causation. Patients who take GLP-1 drugs may differ from those who do not in ways that independently reduce addiction risk: better healthcare access, more regular physician contact, higher treatment adherence. The researchers controlled for many of these variables, but observational studies carry inherent limits. [1] [4]
Still, the direction of the evidence is consistent enough that the National Institute on Drug Abuse announced in February that it would fund clinical trials of semaglutide for alcohol use disorder. If the trials confirm the observational data, GLP-1 drugs would become the first pharmaceutical class to treat obesity, diabetes, cardiovascular disease, and addiction from a single mechanism. [3]
The drug class that began as a diabetes treatment, expanded into weight loss, and proved cardiovascular benefits now has a plausible claim on the addiction crisis. The scope of what GLP-1 drugs do continues to outrun the research designed to explain why they do it. [4]
-- NORA WHITFIELD, Chicago
Sources & X Posts
News Sources